BR112018072177A2 - composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta - Google Patents

composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta

Info

Publication number
BR112018072177A2
BR112018072177A2 BR112018072177-8A BR112018072177A BR112018072177A2 BR 112018072177 A2 BR112018072177 A2 BR 112018072177A2 BR 112018072177 A BR112018072177 A BR 112018072177A BR 112018072177 A2 BR112018072177 A2 BR 112018072177A2
Authority
BR
Brazil
Prior art keywords
respiratory tract
pharmaceutical composition
nasal congestion
pharmaceutically acceptable
carboxylic acid
Prior art date
Application number
BR112018072177-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Ernst Bettina
Original Assignee
Proponent Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proponent Biotech Gmbh filed Critical Proponent Biotech Gmbh
Publication of BR112018072177A2 publication Critical patent/BR112018072177A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018072177-8A 2016-05-17 2017-05-17 composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta BR112018072177A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16169882 2016-05-17
EP16169882.4 2016-05-17
PCT/EP2017/061832 WO2017198702A1 (en) 2016-05-17 2017-05-17 Carboxylic acid for treating/preventing nasal congestion

Publications (1)

Publication Number Publication Date
BR112018072177A2 true BR112018072177A2 (pt) 2019-02-12

Family

ID=56014856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072177-8A BR112018072177A2 (pt) 2016-05-17 2017-05-17 composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta

Country Status (13)

Country Link
US (1) US20200000751A1 (https=)
EP (1) EP3458043A1 (https=)
JP (1) JP6975473B2 (https=)
KR (1) KR102430892B1 (https=)
CN (1) CN109152754A (https=)
AU (1) AU2017266726A1 (https=)
BR (1) BR112018072177A2 (https=)
CA (1) CA3020485A1 (https=)
CL (1) CL2018003270A1 (https=)
MX (1) MX2018013475A (https=)
RU (1) RU2018143564A (https=)
SG (2) SG10202006016QA (https=)
WO (1) WO2017198702A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11206245B2 (en) * 2009-10-14 2021-12-21 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
US11948678B2 (en) * 2009-10-14 2024-04-02 Trice Imaging, Inc. Systems and devices for encrypting, converting and interacting with medical images
GB202004690D0 (en) * 2020-03-31 2020-05-13 Edinburgh Napier Univ Composition for enhancing immune response of cells
US12414928B2 (en) 2021-05-14 2025-09-16 Rene Dumalaog Javier Viral inactivation spray and gargling formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063363A (en) * 1997-05-27 2000-05-16 Goodwin; Gary J Treatment for upper respiratory tract infections with potassium salts
PL193131B1 (pl) * 1997-12-23 2007-01-31 Schering Corp Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
CA2538760A1 (en) * 2003-09-19 2005-03-31 Otsuka Pharmaceutical Co., Ltd. Human .beta.-defensin secretion promoter
US20070256812A1 (en) * 2006-04-19 2007-11-08 Wen-Chen Wei Multidirectional heat dissipating structure
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
ES2748632T3 (es) * 2012-10-03 2020-03-17 Proponent Biotech Gmbh Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas

Also Published As

Publication number Publication date
SG10202006016QA (en) 2020-07-29
CL2018003270A1 (es) 2019-02-22
KR102430892B1 (ko) 2022-08-09
US20200000751A1 (en) 2020-01-02
RU2018143564A3 (https=) 2020-07-23
CA3020485A1 (en) 2017-11-23
CN109152754A (zh) 2019-01-04
SG11201808322PA (en) 2018-10-30
AU2017266726A1 (en) 2018-10-11
JP2019516797A (ja) 2019-06-20
EP3458043A1 (en) 2019-03-27
WO2017198702A1 (en) 2017-11-23
KR20190009294A (ko) 2019-01-28
JP6975473B2 (ja) 2021-12-01
RU2018143564A (ru) 2020-06-17
MX2018013475A (es) 2019-08-12

Similar Documents

Publication Publication Date Title
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
JP2013155188A5 (https=)
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015009504A2 (pt) inibidores de rock
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
PH12015502274A1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
BR112015029709A2 (pt) dihidroetorfina para o fornecimento de alívio da dor e anestesia
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
BRPI0918593B8 (pt) composição farmacêutica para uso no tratamento de infecções sexualmente transmitidas
BR112015031835A8 (pt) agentes terapêuticos, combinação dos referidos agentes e agente terapêutico adicional, uso dos referidos agentes e da referida combinação para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2723 DE 14/03/2023.